doc_id sent_index relation_id relation trigger trigger_offset arg_num arg_base_np arg_protein arg_domain arg_site arg_sugar PSource SiteSource NProtein NID SiteName sent_text 30905597 0 63 gly glycosylated 37:48 arg1 the activated leukocyte cell adhesion molecule the activated leukocyte cell adhesion molecule OGER activated leukocyte cell adhesion molecule Q61490 Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth. 30385318 4 12 gly deglycosylated 468:481 arg1 human BChE human BChE PUBTATOR BChE 590 Although the X-ray structure of a partially deglycosylated monomer of human BChE was solved 15 years ago, all attempts to determine the 3D structure of the natural full-length glycosylated tetrameric human BChE have been unsuccessful so far. 30385318 4 61 gly glycosylated 600:611 arg1 the natural full-length glycosylated tetrameric human BChE the natural full-length glycosylated tetrameric human BChE PUBTATOR BChE 590 Although the X-ray structure of a partially deglycosylated monomer of human BChE was solved 15 years ago, all attempts to determine the 3D structure of the natural full-length glycosylated tetrameric human BChE have been unsuccessful so far. 29644514 5 26 gly 1[Hex 1112:1116 arg1 The monosaccharide compositions Hex The monosaccharide compositions OGER Hex The monosaccharide compositions of two of the acidic oligosaccharides were [Neu5Ac]1[Hex]6[HexNAc]4[deoxy Hex]2, while those of another two were [Neu5Ac]1[Hex]8[HexNAc]6[deoxy Hex]3. 29530027 7 19 gly isolated 1002:1009 arg2 KGF AND polysaccharide fractions KGF polysaccharide fractions PUBTATOR KGF 2252 METHODS Firstly, the composition of polysaccharide fractions isolated from K. grandifoliola stem bark (KGF), C. sanguinolenta (CSF) and C. citratus (CCF) leaves was assessed. 29644514 3 40 gly Gal 605:607 arg1 Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4) Gal Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4) OGER Gal Q8N6F7 The structures of the four neutral milk oligosaccharides were Fuc(α1-2)Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)Glc (difucosyl lacto-N-neohexaose). 29644514 3 40 gly Gal 605:607 arg1 β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6) Gal β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6) OGER Gal Q8N6F7 The structures of the four neutral milk oligosaccharides were Fuc(α1-2)Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)Glc (difucosyl lacto-N-neohexaose). 29644514 3 54 gly Gal 626:628 arg1 Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4) Gal Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4) OGER Gal Q8N6F7 The structures of the four neutral milk oligosaccharides were Fuc(α1-2)Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)Glc (difucosyl lacto-N-neohexaose). 29644514 3 54 gly Gal 626:628 arg1 β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6) Gal β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6) OGER Gal Q8N6F7 The structures of the four neutral milk oligosaccharides were Fuc(α1-2)Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)Glc (difucosyl lacto-N-neohexaose). 29644514 3 63 gly Gal 562:564 arg1 Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4) Gal Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4) OGER Gal Q8N6F7 The structures of the four neutral milk oligosaccharides were Fuc(α1-2)Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)Glc (difucosyl lacto-N-neohexaose). 29644514 3 63 gly Gal 562:564 arg1 β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6) Gal β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6) OGER Gal Q8N6F7 The structures of the four neutral milk oligosaccharides were Fuc(α1-2)Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)Glc (difucosyl lacto-N-neohexaose). 31409852 0 24 gly Impact 0:5 arg1 human milk oligosaccharide composition Impact human milk oligosaccharide composition OGER Impact Q9P2X3 Impact of maternal characteristics on human milk oligosaccharide composition over the first 4 months of lactation in a cohort of healthy European mothers. 30087707 8 36 gly structures 1127:1136 arg1 β1-integrin 1-integrin structures PUBTATOR 1-integrin 3688 Mechanistic investigations showed that C1GalT1 modified O-glycan structures on β1-integrin and regulated its downstream focal adhesion kinase (FAK) signaling. 31891214 0 114 gly challenge 151:159 arg1 weaned pigs pigs challenge OGER pigs Q96S52 Effects of chitosan nanoparticle supplementation on growth performance, humoral immunity, gut microbiota and immune responses after lipopolysaccharide challenge in weaned pigs. 30217822 9 71 gly glycosylated 1415:1426 arg1 glycosylated full-length FH glycosylated full-length FH PUBTATOR FH 3075 These two structures are the most accurate to date for glycosylated full-length FH. 30626008 13 52 gly 8-amino-3,8-dideoxy-manno-oct-2-ulosonic 1353:1392 arg1 Kdo8N oct-2 Kdo8N OGER oct-2 O15244 The oligosaccharide was characterized by the presence of a residue of 8-amino-3,8-dideoxy-manno-oct-2-ulosonic acid (Kdo8N) and of a d,d-heptose, with both residues being identified in other oligosaccharides from Shewanella species. 30648841 6 4 gly P-glycoprotein 1011:1024 arg1 P-glycoprotein P-glycoprotein PUBTATOR P-glycoprotein 5243 Subsequently, the inner cores of the nanoparticles sustainedly release their cargos in drug-resistant tumor cells to keep the effective drug concentration against the drug efflux mediated by P-glycoprotein. 30001603 3 51 gly 11.7:5.4:3.2:1.0 440:455 arg1 a Gal:Ara:Rha:GlcA ratio 2:1 a Gal:Ara:Rha:GlcA ratio OGER 2:1 P35326 This monosaccharide composition was found similar to that of a commercial Arabic gum which exhibited a Gal:Ara:Rha:GlcA ratio of 11.7:5.4:3.2:1.0. 31581071 7 12 gly glycoprotein 1172:1183 arg1 Carcinoembryonic antigen Carcinoembryonic antigen PUBTATOR Carcinoembryonic antigen 1084 Carcinoembryonic antigen (CEA), a routinely used marker for colon cancer, was used as a test glycoprotein. 31200599 7 48 gly glycoproteins 1317:1329 arg1 ECM glycoproteins ECM glycoproteins OGER ECM glycoproteins Q13201 This method was compared with a well-established label-free quantification (LFQ) approach which rendered similar expressions of different categories of proteins (collagens, ECM glycoproteins, proteoglycans, etc.). 30501912 2 69 gly content 529:535 arg1 ECM ECM content OGER ECM Q13201 Depth-dependent proteoglycan (PG) content, collagen content and collagen orientation in the cartilage extracellular matrix (ECM), and PG content in the pericellular matrix (PCM) were assessed with microscopic and spectroscopic methods. 31792963 4 39 gly cartilage 791:799 arg1 the tendon relevant genes collagen type 1 (Col1) cartilage oligomeric matrix protein the tendon relevant genes collagen type 1 (Col1) OGER cartilage oligomeric matrix protein P49747 Age-related differences in the distribution pattern of tendon fibril thickness and in the expression of the tendon relevant genes collagen type 1 (Col1), Col3, Col5, tenascin-C, decorin, tenomodulin, versican, scleraxis and cartilage oligomeric matrix protein were investigated. 31792963 4 43 gly matrix 812:817 arg1 the tendon relevant genes collagen type 1 (Col1) cartilage oligomeric matrix protein the tendon relevant genes collagen type 1 (Col1) OGER cartilage oligomeric matrix protein P49747 Age-related differences in the distribution pattern of tendon fibril thickness and in the expression of the tendon relevant genes collagen type 1 (Col1), Col3, Col5, tenascin-C, decorin, tenomodulin, versican, scleraxis and cartilage oligomeric matrix protein were investigated. 31792963 4 92 gly oligomeric 801:810 arg1 the tendon relevant genes collagen type 1 (Col1) cartilage oligomeric matrix protein the tendon relevant genes collagen type 1 (Col1) OGER cartilage oligomeric matrix protein P49747 Age-related differences in the distribution pattern of tendon fibril thickness and in the expression of the tendon relevant genes collagen type 1 (Col1), Col3, Col5, tenascin-C, decorin, tenomodulin, versican, scleraxis and cartilage oligomeric matrix protein were investigated. 31419551 2 2 gly ALP 421:423 arg1 monosaccharide composition ALP monosaccharide composition OGER ALP Q7L266 Analysis of monosaccharide composition and structure of one fraction from ALP (ALPN) were analyzed by High Performance Liquid Chromatography (HPLC) and Fourier Transform Infrared Spectoscopy (FT-IR). 31419551 2 28 gly composition 374:384 arg1 ALPN ALPN composition Cterm ALPN Q7L266 Analysis of monosaccharide composition and structure of one fraction from ALP (ALPN) were analyzed by High Performance Liquid Chromatography (HPLC) and Fourier Transform Infrared Spectoscopy (FT-IR). 31419551 2 28 gly composition 374:384 arg1 ALP ALP composition OGER ALP Q7L266 Analysis of monosaccharide composition and structure of one fraction from ALP (ALPN) were analyzed by High Performance Liquid Chromatography (HPLC) and Fourier Transform Infrared Spectoscopy (FT-IR). 31891214 1 38 gly challenge 386:394 arg1 weaned pigs pigs challenge OGER pigs Q96S52 In this study, we aimed to determine the effects of dietary supplementation with chitosan nanoparticles (CNP) on growth performance, immune status, gut microbiota and immune responses after lipopolysaccharide challenge in weaned pigs.